Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid
DOI:
https://doi.org/10.2340/actadv.v103.12324Keywords:
Generalized verrucosis, Bullous pemphigoid, DupilumabAbstract
Abstract is missing (Short communication)
Downloads
References
Sri JC, Dubina MI, Kao GF, Rady PL, Tyring SK, Gaspari AA. Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol 2012; 66: 292-311.
https://doi.org/10.1016/j.jaad.2010.12.011 DOI: https://doi.org/10.1016/j.jaad.2010.12.011
D'Agostino GM, Rizzetto G, Marani A, Marasca S, Candelora M, Gambini D, et al. Bullous pemphygoid and novel therapeutic approaches. Biomedicines 2022; 10: 2844.
https://doi.org/10.3390/biomedicines10112844 DOI: https://doi.org/10.3390/biomedicines10112844
Ling X, Shou X, Lou Y, Ling J, Zhang M, Yu T, et al. Research progress of omalizumab in the treatment of bullous pemphigoid. J Dermatol 2023; 50: 575-587.
https://doi.org/10.1111/1346-8138.16791 DOI: https://doi.org/10.1111/1346-8138.16791
Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621.
https://doi.org/10.3389/fimmu.2022.928621 DOI: https://doi.org/10.3389/fimmu.2022.928621
Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol 2018; 154: 1225-1226.
https://doi.org/10.1001/jamadermatol.2018.2526 DOI: https://doi.org/10.1001/jamadermatol.2018.2526
Shen CP, Zhao MT, Ma L. Spontaneous resolution of verruca vulgaris in a paediatric atopic dermatitis patient treated with dupilumab. J Eur Acad Dermatol Venereol 2022; 36: e396-398.
https://doi.org/10.1111/jdv.17936 DOI: https://doi.org/10.1111/jdv.17936
D'Erme AM, Fidanzi C, Bagnoni G, Pardossi S, Margiotta FM, Janowska A, et al. Effect of dupilumab on genital condylomata: a case report. Sex Transm Infect 2022; 98: 73-73.
https://doi.org/10.1136/sextrans-2021-055301 DOI: https://doi.org/10.1136/sextrans-2021-055301
Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res 2017; 231: 21-33.
https://doi.org/10.1016/j.virusres.2016.11.023 DOI: https://doi.org/10.1016/j.virusres.2016.11.023
Hammad NM, Marei A, El-Didamony G, Mortada Z, Elradi M, Afifi AHM, et al. predictors of the therapeutic response to intralesional bivalent HPV vaccine in wart immunotherapy. Vaccines 2021; 9: 1280.
https://doi.org/10.3390/vaccines9111280 DOI: https://doi.org/10.3390/vaccines9111280
Laageide L, Verhave B, Samkoff L, Looney R, Beck L. Relapsing-remitting multiple sclerosis arising in a patient with atopic dermatitis on dupilumab. JAAD Case Rep 2021; 15: 33-35.
https://doi.org/10.1016/j.jdcr.2021.07.003 DOI: https://doi.org/10.1016/j.jdcr.2021.07.003
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Qijun Wang, Yue Ruan, Fei Guo, Haiqin Zhu, Meng Pan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
